A recent retrospective analysis of a large cohort of patients aged 65 and older with advanced non-small cell lung cancer failed to demonstrate any improvement in survival with the addition of bevacizumab to the platinum doublet in the first-line therapy. A few points have to be made: 1) a vast majority of patients with lung cancer are 65 and older; 2) important including fatal toxicity can occur with the use of bevacizumab; and 3) costs of bevacizumab are significant. Integrating the conclusions of this study into clinical practice and further analysis of underlying physical, psychosocial, and economic hurdles of bevacizumab use in lung cancer patients are certainly justified.
DranitsarisGOrtegaALubbeMS. A pharmacoeconomic modeling approach to estimate a value-based price for new oncology drugs in Europe. J Oncol Pharm Pract2012; 18: 57–67.
2.
OcañaAAmirEVeraF. Addition of bevacizumab to chemotherapy for treatment of solid tumors: similar results but different conclusions. J Clin Oncol2011; 29: 254–256.
3.
ZhuJSharmaDBGraySW. Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non-small cell lung cancer. JAMA2012; 307: 1593–1601.
4.
JemalASiegelRXuJ. Cancer statistics, 2010. CA Cancer J Clin2010; 60: 277–300.
5.
HanrattyBLowsonEHolmesL. Funding health and social services for older people - a qualitative study of care recipients in the last year of life. J R Soc Med2012Apr 25.
